Alexion Pharmaceuticals, Inc. $AZN
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS25
PHASE 3 / 2-320
RECRUITING9
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO32%
Delay Index: of 22 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +3.7 months). See all sponsors →
Open Alexion Pharmaceuticals, Inc. on the live radar map → 📅 $AZN readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| CALYPSO NCT05778071 |
P3 | Active, not recruiting | Chronic Hypoparathyroidism; Endocrine System Diseases | 165 | 2024-11-15 |
| CAEL-101 NCT04512235 |
P3 | Active, not recruiting | AL Amyloidosis | 281 | 2025-04-08 (+32 mo) |
| CAEL-101 NCT04504825 |
P3 | Active, not recruiting | AL Amyloidosis | 125 | 2025-05-10 (+33 mo) |
| ALXN1720 NCT05556096 |
P3 | Active, not recruiting | Generalized Myasthenia Gravis | 260 | 2025-05-27 (-1 mo) |
| HICKORY NCT06079281 |
P3 | Active, not recruiting | Hypophosphatasia | 124 | 2025-07-09 (-3 mo) |
| CHESTNUT NCT06079372 |
P3 | Active, not recruiting | Hypophosphatasia | 43 | 2025-07-23 (+5 mo) |
| I CAN NCT06291376 |
P3 | Active, not recruiting | Immunoglobulin A Nephropathy; IgAN | 584 | 2026-01-05 (-2 mo) |
| MULBERRY NCT06079359 |
P3 | Active, not recruiting | Hypophosphatasia | 30 | 2026-01-06 (+7 mo) |
| Ravulizumab NCT05346354 |
P2/3 | Active, not recruiting | Neuromyelitis Optica Spectrum Disorder | 12 | 2026-06-22 (+4 mo) |
| Ravulizumab NCT05644561 |
P3 | Active, not recruiting | Generalized Myasthenia Gravis; gMG | 12 | 2026-07-15 |
| Danicopan NCT05389449 |
P3 | Active, not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 80 | 2026-08-24 (+8 mo) |
| ECU-NMO-304 NCT06724809 |
P3 | Active, not recruiting | NMOSD; Neuromyelitis Optica Spectrum Disorders | 21 | 2026-12-07 (-4 mo) |
| Gefurulimab NCT06607627 |
P3 | Recruiting | Generalized Myasthenia Gravis; gMG | 12 | 2026-12-15 (-4 mo) |
| Danicopan NCT06449001 |
P3 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria; PNH | 6 | 2027-05-28 (+4 mo) |
| AUTUMN NCT07157787 |
P2 | Recruiting | Primary Membranous Nephropathy | 30 | 2027-07-02 (+4 mo) |
| Ravulizumab NCT07596784 |
P3 | Recruiting | Generalized Myasthenia Gravis; gMG | 20 | 2027-08-24 |
| Tarperprumig NCT07160608 |
P2 | Active, not recruiting | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 78 | 2027-10-11 |
| CONCORD NCT06744647 |
P2 | Active, not recruiting | Antibody-Mediated Rejection; Kidney Transplantation | 47 | 2027-10-11 (+6 mo) |
| AWAKE NCT06830798 |
P3 | Recruiting | Delayed Graft Function; DGF | 450 | 2027-11-30 (-3 mo) |
| DepleTTR-CM NCT06183931 |
P3 | Active, not recruiting | Transthyretin Amyloid Cardiomyopathy | 1182 | 2027-12-06 (-11 mo) |
| Ravulizumab NCT07557420 |
P3 | Recruiting | NMOSD; Neuromyelitis Optica Spectrum Disorder | 19 | 2028-09-19 |
| Ravulizumab NCT07024563 |
P3 | Recruiting | IgAN; IgAVN | 36 | 2028-11-29 (+13 mo) |
| ALACRITY NCT07081646 |
P1/2 | Recruiting | Relapsed AL Amyloidosis; Refractory AL Amyloidosis | 91 | 2029-08-15 |
| LTSAFE-ALXN NCT07789483 |
P3 | Not yet recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 1180 | 2030-07-11 |
| DCMRestore NCT07218887 |
P1/2 | Recruiting | BAG3 Mutation Associated Dilated Cardiomyopathy | 6 | 2032-01-27 (+18 mo) |